ESMO: Merck's Keytruda posts first-in-class victory in pre-surgery breast cancer

Barcelona (Pixabay)
Merck presented the Keynote-522 data Sunday at the ESMO congress in Barcelona. (Pixabay)

BARCELONA—Merck’s Keytruda may have come up short in metastatic triple negative breast cancer over the weekend, but in the pre- and post-surgery settings, it posted a first-of its-kind win.

Among pre-surgery patients, the combination of Keytruda and chemo beat out solo chemo at spurring pathological complete responses—meaning their breast and lymph node tissue showed no signs of residual cancer at surgery. 64.8% of patients receiving Keytruda hit that benchmark, compared with 51.2% of chemo-only patients.

And patients saw that benefit regardless of their levels of biomarker PD-L1, Merck said Sunday at the European Society for Medical Oncology annual meeting.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

That’s an important victory, given that “pathologic complete response is a good predictor of long-term outcomes,” Roy Baynes, M.D., Merck SVP and head of global clinical development, said.

“If a patient who presents with a triple-negative breast mass is treated with a neoadjuvant therapy and achieves a pathological complete response, that person is likely to do well,” he said.

The study, dubbed Keynote-522, had another endpoint, too, looking at Keytruda’s ability to cut the risk of disease recurrence and progression after surgery. Patients who received the drug before surgery went on to receive it afterward, while those on only chemo got placebo.

At a median 15.5 months after treatment—an early interim look-in—Keytruda had slashed the risk of recurrence in the adjuvant setting by 37% compared with the chemo-placebo regimen. And while that benefit isn’t statistically significant, “it does give us a lot of encouragement” about the future of the trial, Baynes said.

“At this moment in time that does not cross a statistical boundary, but the bar was very high because it’s very early in this trial,” he added.

The data were enough to convince U.S. regulators to bestow Keytruda with their breakthrough therapy designation, speeding its path toward approval.

RELATED: ESMO: Merck learns from Keytruda's monotherapy miss in triple-negative breast cancer

Unfortunately for Merck, its immuno-oncology standout hasn’t so far seen the same success in the metastatic TNBC arena. Saturday at ESMO, the company presented detailed results from a trial in which Keytruda monotherapy failed to extend survival in previously treated patients.

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.